Skip to Content

Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma

TUESDAY, Feb. 23, 2021 -- Fecal microbiota transplantation (FMT) together with anti-programmed cell death protein 1 (PD-1) therapy possibly may alter the gut microbiome and overcome resistance to anti-PD-1 in some patients with melanoma, according to a study published in the Feb. 5 issue of Science.

Noting that the composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and cancer patients, Diwakar Davar, M.D., from the University of Pittsburgh, and colleagues assessed the safety and efficacy of responder-derived FMT together with anti-PD-1 in 15 patients with PD-1-refractory melanoma.

The researchers found that the combination was well tolerated, provided clinical benefit in six patients, and induced rapid and durable perturbation of microbiota. In responders, an abundance of taxa increased that were previously shown to be associated with response to anti-PD-1, CD8+ T cell activation increased, and the frequency of interleukin-8-expressing myeloid cells was reduced. Distinct proteomic and metabolomic signatures were seen for responders, and confirmation that the gut microbiome regulated these changes was provided by transkingdom network analyses.

"We expect that future studies will identify which groups of bacteria in the gut are capable of converting patients who do not respond to immunotherapy drugs into patients who do respond," a coauthor said in a statement. "If researchers can identify which microorganisms are critical for the response to immunotherapy, then it may be possible to deliver these organisms directly to patients who need them, without requiring a fecal transplant."

Several authors disclosed financial ties to pharmaceutical companies, including Merck MSD, which funded the clinical trial.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Biomarker May Predict Treatment Outcome in Advanced Melanoma

THURSDAY, Feb. 18, 2021 -- Among patients receiving targeted therapy for advanced melanoma, BRAF V600-mutant cell-free circulating tumor DNA (ctDNA) measurements potentially could...

Global Demand for Cancer Surgery Expected to Climb

MONDAY, Feb. 1, 2021 -- The demand for cancer surgery is projected to increase 52 percent between 2018 and 2040, with the greatest relative increase projected for low-income...

ACG Develops First Guideline for Irritable Bowel Syndrome

TUESDAY, Dec. 22, 2020 -- In a new American College of Gastroenterology clinical guideline, published online Dec. 14 in The American Journal of Gastroenterology, recommendations...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.